Origami Therapeutics was selected as a Finalist at the Start-Up Stadium at BIO 2025!

Beth J. Hoffman, PhD, Founder and CEO of Origami Therapeutics, Inc. was a panelist for: Next-Generation Alzheimer's Disease Therapies As the search for effective treatments for Alzheimer’s disease intensifies, join us for a compelling panel discussion on the...

Learn more about the Protein Degradation for the CNS Summit

Two years ago, we launched the o2h Kickstarter program with the aim of empowering biotech startups at crucial moments in their drug discovery journey. We’re pleased to have supported more than 𝟐𝟎 innovative biotech startups all over the world, helping them progress...

BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? Continue reading...

Read the interview with Beth Hoffman on page 15 of the September 2024 issue of Life Sciences Insights.

Building Exciting Biotech Companies Published Aug 29, 2024 Welcome to Partnology’s Biotech Leader Spotlight Series, where we highlight the remarkable accomplishments and visionary leadership of biotech industry pioneers. This series is about showcasing the...

Origami Therapeutics is now on Y Combinator! Learn more about Y Combinator Funded Companies

The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down.... Learn more

Our CEO, Beth Hoffman, shares some of her insights into how to approach novel CNS targets by targeting the root cause in order to to slow or halt disease progression on pg. 24 of the latest issue of California Life Sciences digital magazine, Life Sciences Insights....

Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in...

The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down. Origami Therapeutics is using its proprietary drug discovery platform to...

Protein degradation is an up-and-coming approach that most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. Read full article

Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain, and...

Listen to the Podcast

Oral drugs to halt neurodegeneration Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our...

28 Feb – 3 March, 2022 Presenting at 17th Annual Huntington’s Disease Therapeutics Conference https://web.cvent.com/event/a0991146-7ae2-4f10-bc6c-0bf856caac34/summary   28-30 March, 2022 Presenting at 10th Annual Neurodegenerative Drug Development Summit...

Targeted protein degradation (TPD) is emerging to be a promising technology for targeting disease-causing proteins. Through the mechanism of hijacking either the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway the protein of interest is degraded,...

Learn more about Origami, one of Biocenturys 2021 class of emerging companies.

See the BioTech Showcase Agenda